Episode

Real-world availability of CAR T-cell therapies

Podcast
Blood Podcast
Published
Apr 16, 2026
Duration seconds
598
Processing state
not_requested
Canonical source
https://share.transistor.fm/s/1a6a718d
Audio
https://prfx.byspotify.com/e/media.transistor.fm/1a6a718d/89e44675.mp3
JSON
/v1/public/podcasts/blood-podcast-664776/episodes/real-world-availability-of-car-t-cell-therapies
Markdown
/podcast/blood-podcast-664776/real-world-availability-of-car-t-cell-therapies.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/real-world-availability-of-car-t-cell-therapies/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/blood-podcast-664776/real-world-availability-of-car-t-cell-therapies.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this week's episode, Blood podcast editor Laurie Sehn interviews Drs. Edward Cliff on his latest research published in volume 147 issue 14 of Blood . Dr. Cliff discusses " Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries " which maps the mismatch between innovation and implementation across high-income and selected-upper-middle-income countries for US Food and Drug Administration–approved products and indications.